相关临床试验
25
1 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
进行中（未招募）
1
4.0%
已完成
7
28.0%
招募中
5
20.0%
终止
11
44.0%
撤回
1
4.0%
暂无批准数据
- NexImmune's lead candidate NEX-ILE12, a novel interleukin-12 immunomodulator, has shown promising safety profiles and immune activation signals in Phase 1 trials for solid tumors. - The company reported dose-escalation progress without dose-limiting toxicities and plans to initiate combination studies with PD-1 inhibitors by mid-2026. - NexImmune's proprietary Artificial Immune Modulation (AIM) technology differentiates the company by mimicking natural immune synapses, potentially improving efficacy over existing CAR-T approaches. - The company maintains a cash position supporting operations into 2027, though high R&D expenses and potential dilution from future raises remain concerns for investors.
- Fate Therapeutics' FT819 off-the-shelf CAR-T therapy demonstrated meaningful disease reduction in 12 systemic lupus erythematosus patients with a favorable safety profile and no dose-limiting toxicities. - The therapy achieved up to 78% reduction in disease activity scores at six months, with 5 out of 10 patients achieving clinical remission without intensive conditioning chemotherapy. - The company plans to initiate a registrational trial for FT819 in 2026 following FDA discussions under its Regenerative Medicine Advanced Therapy designation. - Two next-generation CAR-T programs, FT836 for multiple myeloma and FT839 for B-cell malignancies, showed enhanced potency and targeting capabilities in preclinical studies.
- A comprehensive analysis of immunology collaboration and licensing deals reveals 909 transactions between leading biopharma companies from 2016 to 2025, providing unprecedented insight into deal structures and financial terms. - The report provides detailed access to deal payment terms including upfront payments, milestone payments, and royalty rates, offering critical benchmarking data for industry negotiations. - Major pharmaceutical companies including Pfizer, Novartis, Johnson & Johnson, Amgen, and Genentech are among the most active dealmakers in the immunology space according to the analysis. - The comprehensive directory organizes deals by company, therapeutic target, and technology type, with access to actual contract documents submitted to the Securities Exchange Commission.
- Fate Therapeutics presented compelling Phase 1 results for FT819, an off-the-shelf CAR-T therapy targeting systemic lupus erythematosus, at ACR Convergence 2025. - The study demonstrated significant therapeutic effects across ten patients, showing rapid and sustained CD19+ B-cell depletion and improved disease activity scores without prior conditioning chemotherapy. - The company has secured FDA RMAT designation and plans to initiate a pivotal study by 2026, potentially accelerating the path to market approval. - Following the clinical data release, Fate Therapeutics' stock surged more than 60% from annual lows, though analyst opinions remain divided with price targets ranging from $3.70 to $7.00.
- Fate Therapeutics is conducting two Phase 1 clinical studies evaluating off-the-shelf CAR-T cell therapies FT836 and FT825 for advanced solid tumors including lung, colorectal, breast, ovarian, and HER2-positive cancers. - The FT836 study, which began in October 2025, tests the therapy alone or combined with chemotherapy and monoclonal antibodies like trastuzumab and cetuximab to establish recommended Phase 2 dosing. - The FT825 study, initiated in January 2024, focuses on HER2-positive and other advanced solid tumors, evaluating the therapy with or without cetuximab to assess safety, tolerability, and antitumor activity. - Both studies represent significant advances in off-the-shelf CAR-T cell therapy development, potentially positioning Fate Therapeutics as a leader in innovative cancer treatments for solid tumors.
- Major pharmaceutical and biotech companies including Pfizer, Johnson & Johnson, Fate Therapeutics, and Generation Bio are implementing workforce reductions as part of industry-wide financial restructuring efforts. - Companies are shifting from broad R&D portfolios to focused pipeline optimization, with firms like Shattuck Labs and Relay Therapeutics narrowing their therapeutic focus to core projects with highest potential returns. - The layoffs reflect strategic responses to investor pressure for capital discipline, post-pandemic demand shifts, and the need to extend cash reserves while maintaining progress on lead clinical programs. - Industry consolidation and increased outsourcing to contract research organizations are driving operational realignment, as companies seek to reduce overhead costs and access specialized expertise without maintaining high-cost facilities.
- Fate Therapeutics will present five studies on its iPSC-derived CAR T-cell therapy platform at the upcoming ASGCT Annual Meeting, highlighting potential applications across autoimmune diseases and cancer. - The company's lead candidate FT522, featuring novel Alloimmune Defense Receptor technology, will be featured in an oral presentation showing how it may eliminate the need for conditioning chemotherapy in patients. - Preclinical data will demonstrate Fate's progress in developing off-the-shelf cell therapies targeting solid tumors, including FT836, a novel MICA/B-targeting CAR T-cell therapy with broad activity across multiple cancer types.
- Design Therapeutics has appointed Chris Storgard, M.D., as Chief Medical Officer, bringing over two decades of leadership in drug development with experience advancing multiple assets through global regulatory approvals. - Dr. Storgard previously served as CMO at ADARx Pharmaceuticals and Heron Therapeutics, where he secured U.S. and European approvals for several products in oncology and acute care. - The appointment comes at a strategic time as Design Therapeutics advances its portfolio of GeneTAC® small molecules targeting serious degenerative genetic diseases, including its lead program for Friedreich ataxia.
- CRISPR-Cas9 gene editing is being used to enhance CAR-NK cell therapy by disrupting inhibitory genes like KLRC1, TGFBR2, CISH, and CD38 to improve cytotoxicity and metabolic fitness. - Over 60 CAR-NK clinical trials are registered, but none have achieved approval due to challenges including short lifespan, low proliferation, poor tumor trafficking, and immunosuppressive tumor microenvironments. - Gene manipulation strategies are addressing key bottlenecks by reducing immunogenicity, enhancing cytotoxicity through modified CD16 receptors, and improving persistence through IL-15 armoring. - Novel approaches include disrupting immune checkpoints, preventing fratricide through targeted gene deletion, and incorporating safety switches for selective cell elimination in case of adverse events.
- The NK cell therapy market is experiencing robust growth driven by increasing interest in immuno-oncology and advancements in cell engineering technologies, with significant expansion expected through 2034. - Leading companies including Artiva Biotherapeutics, Glycostem, Fate Therapeutics, and Senti Biosciences are developing promising therapies such as AlloNK, oNKord, and FT522, with several receiving FDA designations for expedited development. - Off-the-shelf NK cell therapies are emerging as a key trend, offering advantages in manufacturing scalability, immediate availability, and potential applications beyond oncology into autoimmune diseases.
